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ABSTRACT
OBJECTIVE.Gonadotropin-releasing hormone analogs revolutionized the treatment of
central precocious puberty. However, questions remain regarding their optimal use
in central precocious puberty and other conditions. The Lawson Wilkins Pediatric
Endocrine Society and the European Society for Pediatric Endocrinology convened a
consensus conference to review the clinical use of gonadotropin-releasing hormone
analogs in children and adolescents.
PARTICIPANTS.When selecting the 30 participants, consideration was given to equal
representation from North America (United States and Canada) and Europe, an
equal male/female ratio, and a balanced spectrum of professional seniority and
expertise.
EVIDENCE. Preference was given to articles written in English with long-term outcome
data. The US Public Health grading system was used to grade evidence and rate the
strength of conclusions. When evidence was insufficient, conclusions were based on
expert opinion.
CONSENSUS PROCESS. Participants were put into working groups with assigned topics and
specific questions. Written materials were prepared and distributed before the con-
ference, revised on the basis of input during the meeting, and presented to the full
assembly for final review. If consensus could not be reached, conclusions were based
on majority vote. All participants approved the final statement.
CONCLUSIONS. The efficacy of gonadotropin-releasing hormone analogs in increasing
adult height is undisputed only in early-onset (girls 6 years old) central precocious
puberty. Other key areas, such as the psychosocial effects of central precocious
puberty and their alteration by gonadotropin-releasing hormone analogs, need ad-
ditional study. Few controlled prospective studies have been performed with gona-
dotropin-releasing hormone analogs in children, and many conclusions rely in part
on collective expert opinion. The conference did not endorse commonly voiced
concerns regarding the use of gonadotropin-releasing hormone analogs, such as
promotion of weight gain or long-term diminution of bone mineral density. Use of
gonadotropin-releasing hormone analogs for conditions other than central preco-
cious puberty requires additional investigation and cannot be suggested routinely.
Pediatrics 2009;123:e752–e762
GONADOTROPIN-RELEASING HORMONE ANALOGS (GnRHas) are standard of care for treatment of central precociouspuberty (CPP). However, despite a favorable record of safety and efficacy, significant questions remain
regarding their use. The European Society for Pediatric Endocrinology (ESPE) and the Lawson Wilkins Pediatric
Endocrine Society (LWPES) convened a consensus conference to examine GnRHa therapy in pediatric patients. We
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operational definition of precocious puberty as puberty




Consideration was given to equal representation from
North America (United States and Canada) and Europe,
an equal male/female ratio, and a balanced spectrum of
professional seniority and expertise.
Process
Thirty participants were put into 1 of 6 groups with
assigned topics and designated chairpersons. Each par-
ticipant prepared a summary of the literature regarding
a question that was distributed before the conference
(held over 3 days in November 2007). Each group re-
vised the summaries and presented them to the full
conference. If consensus could not be reached, conclu-
sions were made on the basis of a vote of all participants.
This report is organized around the questions that were
addressed; it has been approved by the participants and
endorsed by the LWPES and ESPE.
Evaluation of Evidence
Preference was given to articles written in English with
long-term outcome data published between 1990 and
2007. The US Public Health grading system1 was used to
grade the evidence and strength of the recommenda-
tions.* Grading was reviewed by the full conference
under the guidance of a methodologist/biostatistician.
This report is a not a practice guideline; nonetheless, we
aimed to adhere to modified appraisal of guidelines re-
search and evaluation (AGREE) criteria.2
INITIATION OF GnRHa THERAPY FOR CPP
Clinical Criteria
The most important clinical criterion for GnRHa treat-
ment is documented progression of pubertal develop-
ment, which is based on the recognition that many
patients with CPP have a slowly progressive or nonpro-
gressive form and achieve adult height (AH) within their
target range without GnRHas.3–7 Accelerated growth ve-
locity and skeletal maturation are other features of sus-
tained and/or rapidly progressing CPP.8 However, some
patients with slowly progressive CPP and advanced bone
age (BA) reach normal AH without intervention.3
Conclusions: Progressive pubertal development and
growth acceleration should be documented over a 3- to
6-month period before GnRHa therapy. This observa-
tional period may not be necessary if the child is at or
past Tanner stage III (breast), particularly with advanced
skeletal maturation (CIII).
Chronological Age and Psychosocial Criteria
Common reasons for GnRHa therapy are potential for
compromise in adult stature, inability to adapt oneself to
menarche, and psychosocial difficulties. Most of the ev-
idence concerns height outcomes (predicted versus ac-
tual AH) and age at initiation of therapy, but no ran-
domized, controlled trials quantifying the effect of
therapy on AH are available. The Bayley-Pinneau
method is commonly used to predict AH and is likely
better than other prediction methods9; however, in some
instances, it may overpredict height by several centime-
ters.10,11
The greatest height gain has been observed in girls
with onset of puberty at 6 years (average gain 9–10
cm, but with variation among studies6,12–16). Girls with
onset between 6 and 8 years comprise a heterogeneous
group that may have a moderate benefit ranging from
4.5  5.813 to 7.2  5.3 cm.6 Insufficient data exist to
relate CA to height outcomes among boys.17
Data regarding the psychosocial impact of untreated
or treated CPP are inconclusive, and whether delaying
puberty with GnRHas may improve social functioning is
still an open question. Early menarche in the general
population is associated with risk-taking behavior,18 but
it is unclear whether such data can be generalized to
CPP. In patients with severe developmental delay, CPP
may be associated with inappropriate behavior. If sup-
pression of menses is the primary goal, GnRHas are only
one of several therapeutic options, including progesto-
gens, that could be considered.19
Conclusions: Girls with onset of progressive CPP be-
fore 6 years of age benefit most in terms of height from
GnRHas. The decision to initiate therapy in girls with
onset after the age of 6 should be individualized (BII).
Treatment should be considered for all boys with onset
of progressive CPP before 9 years of age who have com-
promised height potential (CIII). The use of GnRHas
solely to influence the psychosocial consequences of CPP
or to delay menarche should be considered carefully
given the absence of convincing data (CIII). Additional
studies to evaluate the effects of GnRHa therapy on
quality of life and psychosocial functioning are needed.
Adopted Children
Boys and girls adopted internationally are at risk of CPP,
although data are limited for boys.20,21 Response to Gn-
RHas in adopted girls with precocious or early normal
puberty seems comparable with that seen in nonadopted
girls.22 Adopted children may be at increased risk of
emotional and behavioral problems,23 but no data are
available to demonstrate that GnRHa therapy improves
psychological well-being.24
Conclusions: Although international adoption consti-
tutes a risk factor for CPP, adopted children should be
treated no differently than nonadopted children with
CPP (CIII).
Hormonal Criteria
Luteinizing hormone (LH) measurements are the most
valuable biochemical parameter for the diagnosis of CPP.
*The qualities of evidence are I (data from1 properly randomized, controlled trial), II (data
fromother clinical studies), and III (data fromopinions of respected authorities based on clinical
experience, descriptive studies, or reports of expert committees), and the strengths of recom-
mendation areA (goodevidence to support use), B (moderate evidence to support use), C (poor
evidence to support recommendation), D (moderate evidence against use), and E (strong
evidence against use).
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Because prepubertal LH levels are 0.1 IU/L, LH assays
used should have a detection limit near 0.1 IU/L.25–27 In
1 study of normal children, basal LH levels distinguished
prepubertal (LH  0.2 IU/L) and pubertal males with
100% sensitivity and specificity, but 50% of the girls
with Tanner stage 2 breasts had levels in the prepubertal
range.27
LH can be measured after stimulation with GnRH
(single serum sample at 30–40 minutes27–29) or with a
GnRHa such as aqueous leuprolide (single sample at 60
minutes30,31). Peak LH values show an overlap between
prepubertal and early pubertal children. As with basal
LH, variability among assays and paucity of normative
data have hampered the development of diagnostic cut-
offs for CPP, although an (assay-specific) prepubertal
limit of peak LH at 3.3 to 5.0 IU/L has been suggest-
ed.25,27,28
LH levels provide more information than those of
follicle-stimulating hormone (FSH). However, the stim-
ulated LH/FSH ratio may help differentiate progressive
CPP (which tends to have higher LH/FSH ratios) from
nonprogressive variants that do not require GnRHa ther-
apy.32–34
For estradiol, the most sensitive measurements (tan-
dem mass spectrometry) have shown that prepubertal
levels may be 1 pg/mL (3.7 pmol/L) and undetectable
with commonly available assays.35 Thus, in non–mass
spectrometry assays, measurable estradiol only confirms
relatively advanced puberty. Similarly, testosterone as-
says with detection limits of10 ng/dL may not discrim-
inate prepubertal from early pubertal levels.36 For estra-
diol and testosterone, the laboratory used must have a
defined prepubertal range.
Conclusions: Sensitive assays with pediatric norms
should be used and stimulation results interpreted de-
pending on the agent used (BII). The same caveats are
important if hormonal testing is used to monitor therapy
(see below). Basal LH levels are useful screening tests
and may be diagnostic (BII). Stimulated LH levels are
important, but interpretation suffers from assay variabil-
ity and absence of clear diagnostic cutoffs (BII). Gonadal
sex-steroid levels can add information in support of the
diagnosis but are not sufficient (BII).
Pelvic Ultrasound
Female patients with CPP have increased ovarian and
uterine dimensions compared with prepubertal controls
and girls with premature thelarche.37 For CPP, cutoff
values for uterine length range from 3.4 to 4.0 cm. The
presence of an endometrial echo is highly specific
(100%) but less sensitive (42%–87%).34 The cutoffs
for a pubertal ovarian volume range between 1 and 3 mL
(volume  length  width  height  0.5233).38
Conclusions: Pelvic ultrasound is helpful in differen-
tiating CPP from premature thelarche as an adjunct to
GnRH stimulation (BII).
Central Nervous System Imaging
CPP may be a sign of central nervous system pathology.
Unsuspected intracranial pathology has been reported in
8% of girls39,40 and 40% of boys41 without neurologic
findings or neurofibromatosis. The percentage of chil-
dren with unsuspected intracranial pathology decreases
with age.39–41 Only 2% to 7% of girls who have onset of
CPP between the ages of 6 and 8 years have unsuspected
pathology, and only1% have a tumor such as a glioma
or astrocytoma.39,40 Factors that may decrease the likeli-
hood of finding a tumor include racial/ethnic back-
ground, family history of CPP, and adoption.
Conclusions: All boys with CPP and girls with CPP at
6 years of age should have a head MRI. It is contro-
versial whether all girls who develop CPP between 6 and
8 years of age require head MRI. Girls with neurologic
findings and rapid pubertal progression are more likely
to have intracranial pathology and require an MRI ex-
amination (BII).
AVAILABLE GnRHas AND THERAPEUTIC REGIMENS FOR CPP
Currently Available Therapeutic Regimens
All available GnRHas are effective despite their different
routes of administration, dosing, and duration of action
(Tables 1–3).42,43 The depot preparations are preferred be-
TABLE 1 Characteristics of GnRHas
Rapid Acting Monthly Depot 3-mo Depot 12-mo Implant
Dosing 3–4 times daily (intranasal) or
every day (subcutaneous)
Every 28 d Every 90 d Every year
Peak serum
concentrations
10–45 min 4 h 4–8 h 1 mo
Onset of therapeutic
suppression
2–4 wk 1 mo 1 mo 1 mo
Advantage Quick on/off Dosing and efﬁcacy well studied Fewer injections and fewer
compliance concerns
No injections needed




Painful injection Requires surgical procedure for
insertion and removal
TABLE 2 Rapid-Acting Formulations of GnRHa
GnRHa Administration Starting Dose, per day
Nafarelin Nasal spray 800 g twice
Buserelin Nasal spray 20–40 g/kg
Buserelin Subcutaneous 1200–1800 g
Leuprolide Subcutaneous 50 g/kg
Deslorelin Subcutaneous 4–8 g/kg
Histrelin Subcutaneous 8–10 g/kg
Triptorelin Subcutaneous 20–40 g/kg
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cause of improved compliance.44–46 In most children,
monthly injections adequately suppress the gonadotropic
axis, but some children require more frequent injections or
higher-than-standard doses. The 3-month formulations
are comparable with monthly dosing, but no randomized
comparative trial is available.42,47–49 In 1 prospective trial,
7.5 mg of leuprolide monthly suppressed LH more effec-
tively than 11.25 mg every 3 months, although sex-steroid
concentrations were equally inhibited.50 The 50-mg histre-
lin-acetate implant provides sustained suppression for 12
months.51,52
Conclusions: A variety of GnRHa formulations are
available and efficacious. The choice of a particular agent
depends on patient and physician preference and on
local marketing approval (CIII).
Treatment Monitoring
Progression of breast or testicular development is sug-
gestive of treatment failure,52–56 but progression of pubic
hair may indicate normal adrenarche. Growth velocity,
height SD score (SDS), and BA advancement should
decline during treatment. Vaginal bleeding may occur
after the first administration of GnRHas, but subsequent
bleeding suggests lack of efficacy or incorrect diagnosis.
Markedly decreased growth velocity (less than or equal
to a 2 SDS) or rapid BA advancement should also
prompt reassessment. BA can be used to update AH
prediction understanding that the Bayley-Pinneau
method may overestimate AH.57 If elevated, random LH
levels obtained by using an ultrasensitive assay indicate
lack of suppression. Stimulated LH values (using GnRH,
aqueous GnRHas, or the free GnRHas contained in depot
preparations) can also be used to assess effectiveness.
FSH levels are not normally used to monitor suppres-
sion. If measured, testosterone and estradiol levels
should be in a prepubertal range for the assay used.44,51,53–
56,58 No long-term data have provided compelling support
for any specific short-term monitoring scheme.
Conclusions: GnRHa-injection dates should be re-
corded and adherence with the dosing interval moni-
tored (BII). Tanner stage and growth should be assessed
every 3 to 6 months, and BA should be monitored
periodically (BII). There was no consensus about the
routine use of random or stimulated measurements of
gonadotropins or sex steroids for monitoring therapy.
For patients with suboptimal clinical response, there was
consensus about need for comprehensive reassessment
(CIII). Additional information on the relationship be-
tween on-treatment measures of gonadotropic axis sup-
pression and outcomes are needed.
Adverse Events
GnRHas are generally well tolerated in children and
adolescents. Systemic complaints such as headaches or
hot flashes occur occasionally but are usually short-term
and do not interfere with therapy. Local adverse events
occur in 10% to 15% of patients and necessitate a
change in agent when persistent, because they can result
in sterile abscesses in a fraction of the patients.54,55,59
Although exceedingly rare, anaphylaxis has been de-
scribed.
Potential New Therapeutic Agents for the Treatment of CPP
GnRH antagonists cause immediate and direct inhibition
at the level of pituitary GnRH receptors.60 Theoretical
advantages over GnRHas include eliminating the initial
“flare” in gonadotropic axis activation and rapid recov-
ery of suppression once therapy is withdrawn. Depot
and nonpeptide orally active GnRH antagonists are un-
der development61 and could be evaluated in children
with CPP in the future.
Therapeutic Agents That Can Be CombinedWith GnRHas for
the Treatment of CPP
Adjunctive therapies that may improve outcomes (AH,
for example) of GnRHa therapy include pure or selective
estradiol estrogen receptor blockers, aromatase inhibi-
tors,62 pure antiandrogens, sex steroids,63 or nonaroma-
tizable anabolic steroids.64 The addition of oxandrolone
increased AH compared with GnRHas alone in a small
(n 10) nonrandomized study.64 The addition of growth
hormone (GH) increased AH compared with GnRHas
alone in girls with CPP and slow growth velocity in small
(n  10 and 17) nonrandomized series.65,66 The addition
of GH increased height outcome in a randomized, con-
trolled study (n 46) of adopted girls with precocious or
early puberty.22 However, to date, no large-scale ran-
domized, controlled trials evaluating the addition of GH
to GnRHas for CPP have been performed.
Conclusions: The addition of GH or oxandrolone to
GnRHas cannot be routinely recommended. These ad-
junctive therapies require validation by larger studies
with consideration for potential adverse effects (CIII).
DISCONTINUATION OF GnRHa THERAPY IN CPP
Factors that could influence the decision to stop GnRHa
treatment depend on the primary goal(s) of therapy,
including maximizing height, synchronizing puberty
with peers, ameliorating psychological distress, and fa-
cilitating care of the developmentally delayed child.
Available data only permit analysis of factors that affect
AH among girls.
TABLE 3 Depot GnRHa Formulations42,47,48
Depot
Preparation
Brand Name Starting Dose
Goserelin Zoladex LA 3.6 mg every month or 10.8 mg
every 3 mo
Buserelin Suprefact depot 6.3 mg every 2 mo
Leuprolide Enantone or
Lupron-depot
3.75 mg every month or 11.25
mg every 3 mo
Prostap SR 3.75 mg every month
Lupron depot PED 7.5, 11.25, or 15 mg every month
(0.2–0.3 mg/kg per mo) or
11.25 mg every 3 moa
Triptorelin Decapeptyl,
Gonapeptyl
3 or 3.75 mg every month or
11.25 mg every 3 mo
Histrelin Supprelin LA 50 mg implant every year
a No data are available on the use of the 22.5-mg 3-month depot in children.
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Treatment Duration
Several studies have reported a direct relationship be-
tween treatment duration and AH14,15,67–69 and an inverse
relationship between age at pubertal onset or at initia-
tion of therapy and AH.6,14,67–69 However, deciphering the
respective influences of age at onset of puberty, age at
initiation of therapy, and treatment duration is problem-
atic, because these variables are interrelated. Undue de-
lay in initiation of therapy (1–2 years) may compro-
mise AH.
Parent/Patient Preference, Anticipated Time of Menarche, CA,
and BA
In the studies we examined, wishes of the patient and
family and the physician’s decision were stated as decid-
ing factors for cessation of treatment.13,15,68,70–73 The mean
age at treatment discontinuation ranged from 10.6 to
11.6 years, with mean BA ranging from 12.1 to 13.9
years and mean age at menarche of 12.3 years. Dis-
continuation at a CA of11.0 years13 and a BA of12.0
years14,67 has been associated with maximum AH. How-
ever, BA is not an appropriate single variable, because a
BA of 12.0 years can be observed at different CAs and
because BA is unreliable for predicting height gain after
treatment.12–15,72 One study has suggested that height
gain after treatment may be higher for those with early
(6 years) versus late treatment.6
Height and Growth Velocity
Although growth velocity during therapy6,13–15,67–69,71,72
and height at interruption of therapy are positively as-
sociated with AH,6,13,14 they cannot be used as indepen-
dent factors for deciding when to stop treatment. For a
child with unexplained marked deceleration of growth,
consideration might be given to stopping treatment or to
introducing adjunct therapies.
Conclusions: There is insufficient evidence to rely on
any one clinical variable (CA, duration of therapy, BA,
height, target height, growth velocity) to make the de-
cision to discontinue treatment (CIII). Therefore, it is
reasonable to consider these parameters and informed
parent and patient preferences, with the goal of men-
arche occurring near the population norms (CIII).
OUTCOMES OF GnRHa THERAPY FOR CPP
Reproductive Function
Follow-up studies have been performed with girls in
their late teens68,69,74–76 and women up to 31 years in 1
study77 and have reported that ovarian function was not
impaired.68,69,74,75,78,79 Menses began 2 to 61 months
(mean: 16 months) after the end of treatment.69,74–77
Regular ovarian cycles occurred in 60% to 96% of the
patients, without differences from reference popula-
tions.69,74–77 Infertility has not been reported. Of 28 re-
ported pregnancies,69,74,75,77 7 were terminated and 21
resulted in healthy children.69,75,77 Three small studies
showed no differences from controls in gonadal function
for boys at the ages of 15 to 18 years.68,78,79 Paternity rates
have not been reported.
Conclusions: The available data suggest that gonadal
function is not impaired in girls treated with GnRHas
(BII). Nevertheless, available data are limited. Long-term
data on fecundity and ovarian reserve of treated patients
with CPP are needed.
BMI and Correlates of Metabolic Syndrome
Childhood obesity is associated with earlier pubertal de-
velopment in girls, and early sexual maturation is asso-
ciated with increased prevalence of overweight and obe-
sity. There has been concern that GnRHa therapy may
affect BMI. Eleven studies addressed BMI outcome in
girls with CPP,6,12,49,69,75,80–85 2 included boys,78,80 and 1
included girls with early puberty (onset at the ages of 8
and 9 years).86 Before GnRHa treatment, mean BMI SDS
was above average in girls with CPP in all studies,
whereas results were split in boys.78,80 The combined
analysis indicates that BMI SDS did not increase after
treatment irrespective of age at presentation. At AH,
mean BMI SDS ranged from 0.1 to 1.7, with an overall
slight decrease from pretreatment BMI. No reports re-
garding metabolic syndrome and GnRHa treatment were
identified.
Conclusions: Above-average BMI is frequent at diag-
nosis of CPP. Long-term GnRHa treatment does not
seem to cause or aggravate obesity, as judged from BMI
(BII). Studies of body composition and fat distribution
are needed.
Bone Mineral Density
Bone mineral density (BMD) may decrease during Gn-
RHa therapy. However, subsequent bone mass accrual is
preserved, and peak bone mass does not seem to be
negatively affected by treatment.12,82,87 There is some
suggestion that discontinuation of treatment in girls with
a BA of11.5 years may lead to greater BMD87 and that,
as in all adolescents, optimum calcium and vitamin D
intake and skeletal-loading exercise may positively in-
fluence bone mass.82
Conclusions: Young adults treated with GnRHas for
CPP in childhood ultimately accrue BMD within the
normal range for age (BII).
Risk of Polycystic Ovarian Syndrome
The possibility that CPP is a first manifestation of poly-
cystic ovarian syndrome (PCOS) has been raised.88 PCOS
occurred in 0% to 12% of girls with CPP followed pro-
spectively12,89–91 compared with 5% to 10% in the gen-
eral population.92 Single studies have reported (1) an
increased average ovarian size after CPP resulting from
hypothalamic hamartoma,75 (2) a higher prevalence of
exaggerated adrenarche in patients with CPP than in
controls,93 and (3) the occurrence of signs of PCOS 0.5 to
4.0 years after menarche.94
Conclusions: Follow-up of treated or untreated girls
with CPP into the midteenage years suggests that the
development of PCOS (BII) or polycystic ovary morphol-
ogy (CIII) is not clearly different from that in the general
population. Premature adrenarche and early childhood
insulin resistance are potential risk factors for PCOS, but
it is not clear if the presence of these conditions along
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with CPP increases the eventual risk of PCOS (CIII).
Longitudinal data through adolescence are needed.
PSYCHOSOCIAL DEVELOPMENT
Potential psychological consequences of CPP, including
risk for emotional distress and problem behavior, are
often used to justify treatment with GnRHas.95,96 Hor-
monally induced behavioral changes (eg, aggression,
sexuality) that occur during normal puberty97 may occur
earlier in children with CPP, perhaps consistent with the
hormonal effects on brain development observed in ro-
dents.98
Limited data are available regarding psychological
consequences of CPP, and the few existing studies have
limitations that have yielded inconsistent conclusions.99
In 2 studies examining psychological functioning in girls
with CPP before and after treatment,24,100 no consistent
patterns of change were observed. GnRHas have been
suggested to adversely affect mood and cognition in
adults,101 but similar effects have not been evaluated in
children.
Conclusions: There is little evidence to show whether
CPP leads to psychological or behavioral problems or
whether treatment with GnRHas are associated with
improved psychological outcome (CIII). Thus, no recom-
mendations related to psychosocial outcomes are possi-
ble. Controlled studies with standardized instruments
are needed.
USE OF GnRHas FOR CONDITIONS OTHER THAN CPP
Gonadal Protection for Children Undergoing Chemotherapy
Infertility represents one of the main long-term conse-
quences of chemotherapy. Studies that evaluated the
effects of ovarian suppression by GnRHas during chemo-
therapy in adult and adolescent patients have yielded
inconsistent results.102–104 Prospective, randomized trials
in adult women are ongoing (see NCT00196846,
NCT0090844, NCT00380406, NCT00068601 at http://
clinicaltrials.gov/).
Conclusions: Routine use of GnRHas for gonadal pro-
tection in children undergoing chemotherapy cannot be
suggested (CIII).
Increasing AH of ChildrenWith Idiopathic Short Stature
The effect of GnRHa therapy on AH has been evaluated
in girls with idiopathic short stature (ISS) and normal
puberty (8–10 years of age), with a mean gain compared
with predicted height of 0 to 4.2 cm.† In boys with
rapidly progressing puberty, GnRHa therapy increased
AH compared with predicted height.5 The effects of com-
bined GH and GnRHa therapy in children with ISS are
controversial,111 with mean gains of 4.4 to 10 cm with
combination therapy versus 0.5 to 6.1 cm in untreated
controls.112,113 In these studies, one cannot definitively
separate the effects of GH from GnRHas. In 2 random-
ized studies of adopted girls with normal puberty, Gn-
RHas plus GH was compared with GnRHas alone, with a
3-cm height gain demonstrated with combination ther-
apy.22,114 Disadvantages of the use of GnRHas in children
with ISS include absence of pubertal growth accelera-
tion, delayed puberty with potential psychosocial disad-
vantage, and decreased BMD. Long-term follow-up
studies are lacking.
Conclusions: GnRHa therapy alone in children with
ISS and normally timed puberty is minimally effective in
increasing AH, may compromise BMD, and cannot be
suggested for routine use (DII). Combined GnRHa and
GH therapy leads to a significant height gain but may
have adverse effects. Routine use of GnRHas in children
with ISS being treated with GH cannot be suggested
(CIII).
Increasing AH of Children Born Small for Gestational Age
Short children born small for gestational age (SGA) usu-
ally have a normal pubertal timing, although some of
them have rapidly progressing puberty, and may be
treated with GH.92,115 Data on the additional effect of
GnRHas are limited.113
Conclusions: Routine use of the combination of Gn-
RHas and GH in children born SGA cannot be suggested
(CIII).
Increasing AH of ChildrenWith Severe Hypothyroidism
Some children with severe hypothyroidism are at risk for
rapid progression through puberty and diminished AH.
In the only study available, combined GnRHas and levo-
thyroxine and levothyroxine alone produced similar
gains in height SDS.116
Conclusions: Routine use of combined therapy with
GnRH and levothyroxine cannot be suggested (CIII).
Increasing AH of ChildrenWith GH Deﬁciency
Some children with GH deficiency are short at the start of
puberty and at risk for short adult stature. Retrospective
studies that evaluated the addition of GnRHas to GH in-
volved a limited number of subjects and provided contro-
versial results.117–119 Three prospective studies that reported
near-AH or AH have shown an 1-SD height gain,120–122
possibly without detrimental effect on BMD.123
Conclusions: Routine use of combined therapy with
GnRH and GH in GH-deficient children with low pre-
dicted AH at onset of puberty cannot be suggested (CIII).
Increasing AH of ChildrenWith Congenital Adrenal
Hyperplasia
One nonrandomized study examined the effect of com-
bined GH and GnRHa treatment on AH in 14 children
with congenital adrenal hyperplasia (CAH) and normal
or precocious puberty and found a 1-SD increase in AH
in comparison with standard treatment for CAH.124
Conclusions: Additional studies are needed to deter-
mine if GnRHa therapy alone or in combination with GH
should be used in children with CAH and low predicted
AH. Routine use of GnRHas for CAH cannot be sug-
gested (CIII).
ChildrenWith Autism
Conclusions: Despite 1 controversial article reporting
that GnRHas may benefit behavioral symptoms in chil-†Refs 6, 14, 15, 57, 69, 71, 73, and 105–110.
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dren with autism,125 the consensus is that there is no
current evidence for GnRHa therapy for this indication
(CIII).
CONCLUSIONS
Several important observations emerged from this con-
ference. Despite a considerable body of literature on the
use of GnRHas, few rigorously conducted and controlled
prospective studies are available from which to derive
evidence-based recommendations. Most of our conclu-
sions are categorized as CIII, a level of evidence that
underscores the need for additional research in key areas
such as the psychosocial effects of GnRHa treatment for
CPP. The efficacy in increasing AH is undisputed only in
early-onset progressive CPP, which highlights the need
to increase our knowledge of the pathophysiology and
normal limits of puberty and of the physical and psycho-
social consequences of treated and untreated CPP. Our
systematic review also highlighted the lack of objective
support for commonly voiced concerns such as the pro-
pensity for GnRHas to promote weight gain or to lead to
long-term diminution of BMD. Use of GnRHas for con-
ditions other than CPP requires additional investigation
and cannot be routinely suggested.
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